Rare condition

Peripheral neuropathy associated with monoclonal gammopathy

00

studies recruiting now

checking live

00

studies registered in total

checking live

00

countries with a recruiting site

checking live

00

recruiting study posted to date

checking live

Recruiting trials

Fetching live from ClinicalTrials.gov. This condition is not yet in our weekly snapshot; live results only.

Keep watching

Get an email when a new Peripheral neuropathy associated with monoclonal gammopathy study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

A group of conditions, not a single diagnosis

Orphanet classifies “Peripheral neuropathy associated with monoclonal gammopathy” as a category that groups several related conditions. Trials are usually registered under the specific condition, so the figures above may undercount. Browse the conditions in this group or see the classification on Orphanet.

Treatments being studied

1 approved treatment and 42 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Mirogabalin
Phase 3Glutamine (Endari)
Phase 3Omeprazole (Antra)
Phase 3Lidocaine (Alphacaine)
Phase 3Duloxetine
Phase 3Antimony
Phase 3Donaperminogene Seltoplasmid
Phase 3Milnacipran (Milnacipran pierre fabre medicament)
Phase 3Nabiximols (Sativex)

+ 34 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).